We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Northwest Biotherapeutics Inc (QB) | USOTC:NWBO | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -1.08% | 0.46 | 0.451 | 0.469 | 0.475 | 0.45 | 0.469 | 1,740,860 | 21:00:13 |
| | | | | 1 | | | |
| | | | | 4 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 11 | | | |
| | | | | 14 | | | |
| | | | | 15 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 22 | | |
Name
|
| |
Age
|
| |
Position
|
|
Linda F. Powers | | |
64
|
| | Class III Director, Chairperson, President and Chief Executive Officer | |
J. Cofer Black | | |
70
|
| | Class I Director | |
Dr. Alton L. Boynton | | |
75
|
| | Class I Director, Chief Scientific Officer | |
Jerry Jasinowski | | |
81
|
| | Class II Director | |
Dr. Navid Malik | | |
51
|
| | Class III Director | |
Name of Beneficial Owner
|
| |
Number of
Shares Beneficially Owned |
| |
Percentage(1)
|
| ||||||
Officers and Directors | | | | | | | | | | | | | |
Alton L. Boynton, Ph.D.(2)
|
| | | | 11,034,937 | | | | | | 1.6% | | |
Marnix L. Bosch, Ph.D., M.B.A.(3)
|
| | | | 7,997,379 | | | | | | 1.2% | | |
Linda F. Powers(4)
|
| | | | 107,983,329 | | | | | | 14.6% | | |
Leslie J. Goldman(5)
|
| | | | 24,672,742 | | | | | | 3.6% | | |
Dr. Navid Malik(6)
|
| | | | 9,075,000 | | | | | | 1.4% | | |
Jerry Jasinowski(7)
|
| | | | 7,444,204 | | | | | | 1.1% | | |
J. Cofer Black(8)
|
| | | | 1,715,000 | | | | | | *% | | |
Jean M. Davis(9)
|
| | | | 643,055 | | | | | | *% | | |
All executive officers and directors as a group (eight persons)
|
| | | | 170,565,646 | | | | | | 21.3% | | |
Name
|
| |
Age
|
| |
Position
|
|
Linda F. Powers | | |
64
|
| | Class III Director, Chairperson, President and Chief Executive Officer | |
Alton L. Boynton, Ph.D.
|
| |
75
|
| | Class I Director, Chief Scientific Officer | |
Leslie J. Goldman | | |
74
|
| | Senior Vice President, General Counsel | |
Marnix L. Bosch, Ph.D.
|
| |
61
|
| | Chief Technical Officer | |
Jean M. Davis | | |
48
|
| | Chief Financial Officer, Chief Accounting Officer and Interim Chief Information Officer | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
(S) |
| |
Option
Awards ($)(1) |
| |
Total
($) |
| |||||||||||||||
Linda F. Powers
Chairperson, President & Chief Executive Officer |
| | | | 2019 | | | | | $ | 502,000 | | | | | $ | 100,000 | | | | | $ | — | | | | | $ | 602,000 | | |
| | | 2018 | | | | | $ | 502,000 | | | | | $ | — | | | | | $ | 6,698,000 | | | | | $ | 7,200,000 | | | ||
Alton L. Boynton, Ph.D.
Chief Scientific Officer and Secretary |
| | | | 2019 | | | | | $ | 325,000 | | | | | $ | 20,000 | | | | | $ | — | | | | | $ | 345,000 | | |
| | | 2018 | | | | | $ | 325,000 | | | | | $ | — | | | | | $ | 1,528,000 | | | | | $ | 1,853,000 | | | ||
Leslie Goldman
Senior Vice President, General Counsel |
| | | | 2019 | | | | | $ | 375,000 | | | | | $ | 67,000 | | | | | $ | — | | | | | $ | 442,000 | | |
| | | 2018 | | | | | $ | 375,000 | | | | | $ | — | | | | | $ | 4,186,000 | | | | | $ | 4,561,000 | | | ||
Marnix L. Bosch, Ph.D.(2)
Chief Technical Officer |
| | | | 2019 | | | | | $ | 397,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 397,000 | | |
| | | 2018 | | | | | $ | 375,000 | | | | | $ | — | | | | | $ | 260,000 | | | | | $ | 635,000 | | | ||
Jean M. Davis(3)
Chief Financial Officer, Chief Accounting Officer and Interim Chief Information Officer |
| | | | 2019 | | | | | $ | 16,000 | | | | | $ | — | | | | | $ | 500,000 | | | | | $ | 516,000 | | |
Name
|
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| ||||||||||||
Linda F. Powers
Chief Executive Officer and President |
| | | | 37,495,653(1) | | | | | | 1,704,347 | | | | | | 0.23 | | | | | | 5/28/2028 | | |
Alton Boynton
Chief Scientific Officer and Secretary |
| | |
|
3,402,935(2) |
| | | | | — | | | | | | 0.25 | | | | | | 6/13/2027 | | |
| | | 4,686,959(3) | | | | | | 213,041 | | | | | | 0.23 | | | | | | 5/28/2028 | | | ||
| | | 2,472,557(4) | | | | | | 494,508 | | | | | | 0.23 | | | | | | 8/31/2028 | | | ||
Leslie J. Goldman
Senior Vice President and General Counsel |
| | | | 23,434,776(5) | | | | | | 1,065,224 | | | | | | 0.23 | | | | | | 5/28/2028 | | |
Marnix L. Bosch
Chief Technical Officer |
| | |
|
31,770(6) |
| | | | | 21,355 | | | | | | 11.20 | | | | | | 6/23/2022 | | |
| | | 15,625(7) | | | | | | — | | | | | | 8.80 | | | | | | 8/20/2022 | | | ||
| | | 7,940,182(8) | | | | | | — | | | | | | 0.25 | | | | | | 6/13/2027 | | | ||
Jean M. Davis
Chief Financial Officer, Chief Accounting Officer and Interim Chief Information Officer |
| | | | —(9) | | | | | | 3,000,000 | | | | | | 0.22 | | | | | | 12/9/2029 | | |
Name
|
| |
Year
|
| |
Fees Earned
or Paid in Cash ($) |
| |
All Other
Compensation ($) |
| |
Option
Awards ($)(1) |
| |
Total
($) |
| |||||||||||||||
Dr. Navid Malik
|
| | | | 2019 | | | | | | 150,000 | | | | | | — | | | | | | — | | | | | | 150,000 | | |
Jerry Jasinowski
|
| | | | 2019 | | | | | | 150,000 | | | | | | — | | | | | | — | | | | | | 150,000 | | |
J. Cofer Black
|
| | | | 2019 | | | | | | 150,000 | | | | | | — | | | | | | — | | | | | | 150,000 | | |
1 Year Northwest Biotherapeutics (QB) Chart |
1 Month Northwest Biotherapeutics (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions